Since the brain, skin, and kidney tumors associated with TSC are vascular [39] and TSC2 loss is associated with increased levels of HIF and VEGF in cultured cells [40], VEGF is a potential target for TSC treatment. This evidence concerns the gene VEGFA and kidney neoplasm.